AU2003273428A1 - Chromosome 6 and 9 genes involved in premature canities - Google Patents

Chromosome 6 and 9 genes involved in premature canities

Info

Publication number
AU2003273428A1
AU2003273428A1 AU2003273428A AU2003273428A AU2003273428A1 AU 2003273428 A1 AU2003273428 A1 AU 2003273428A1 AU 2003273428 A AU2003273428 A AU 2003273428A AU 2003273428 A AU2003273428 A AU 2003273428A AU 2003273428 A1 AU2003273428 A1 AU 2003273428A1
Authority
AU
Australia
Prior art keywords
genes
hla
chromosome
whereof
modifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003273428A
Other versions
AU2003273428A8 (en
Inventor
Stylianos Antonarakis
Jean-Louis Blouin
Olivier De Lacharriere
Claire Deloche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0208696A external-priority patent/FR2842104B1/en
Priority claimed from FR0304360A external-priority patent/FR2853532A1/en
Application filed by LOreal SA filed Critical LOreal SA
Publication of AU2003273428A8 publication Critical patent/AU2003273428A8/en
Publication of AU2003273428A1 publication Critical patent/AU2003273428A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention concerns the use of at least one polynucleotide fragment comprising 18 consecutive nucleotides whereof the sequence corresponds to all or part of a human chromosome 6 gene selected among the HLAG, NT__007592.445, NT_007592.446, NT_007592.506, NT_007592.507, NT_007592.508, HSPAIB, G8, NEU1, NG22, BAT8, HLA-DMB, HLA-DMA, BRD2, HLA-DQA1, HLA-DQA2, NT_007592.588, GRM4, RNF23, FLJ22638, NT_007592.459 and NT_007592.457 genes, or whereof the sequence corresponds to all or part of the human chromosome 9 gene selected among the FREQ, NT_030046.18, NT_030046.17, GTF3C5, CEL, CELL, FS, ABO, BARHL1, DDX31, GTF3C4 and Q96MA6 genes, the use of agents capable of modifying the function attached to one of said genes, the use of expression products of one of said genes and use of agents capable of modifying the function of said expression products, for cosmetic, therapeutic or diagnostic applications.
AU2003273428A 2002-07-10 2003-07-09 Chromosome 6 and 9 genes involved in premature canities Abandoned AU2003273428A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0208696A FR2842104B1 (en) 2002-07-10 2002-07-10 GENES INVOLVED IN EARLY CANITIS
FR02/08696 2002-07-10
FR0304360A FR2853532A1 (en) 2003-04-08 2003-04-08 Use of human polynucleotides for treatment, prevention and diagnosis of pigmentation disorders, especially premature whitening of hair, derived from chromosomes 9 or 6
FR03/04360 2003-04-08
PCT/FR2003/002154 WO2004007742A2 (en) 2002-07-10 2003-07-09 Chromosome 6 and 9 genes involved in premature canities

Publications (2)

Publication Number Publication Date
AU2003273428A8 AU2003273428A8 (en) 2004-02-02
AU2003273428A1 true AU2003273428A1 (en) 2004-02-02

Family

ID=30117024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003273428A Abandoned AU2003273428A1 (en) 2002-07-10 2003-07-09 Chromosome 6 and 9 genes involved in premature canities

Country Status (9)

Country Link
EP (1) EP1520044B1 (en)
JP (3) JP2005532411A (en)
AT (1) ATE417128T1 (en)
AU (1) AU2003273428A1 (en)
BR (1) BR0305435A (en)
CA (1) CA2491223A1 (en)
DE (1) DE60325216D1 (en)
ES (1) ES2319406T3 (en)
WO (1) WO2004007742A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395437T1 (en) * 2004-01-15 2008-05-15 Oreal CHROMOSOME 9 POLYMORPHISMS ASSOCIATED WITH PREMATURE CANITIES
FR2865217B1 (en) * 2004-01-15 2012-10-19 Oreal CHROMOSOME 9 POLYMORPHISMS INVOLVED IN EARLY CANITIS
JP5025253B2 (en) * 2006-03-31 2012-09-12 日生バイオ株式会社 Formulation for basic cosmetics and basic cosmetics
FR2930775B1 (en) 2008-04-30 2010-05-21 Oreal USES OF BNIPXL-BETA IN EARLY CANITIS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470577A (en) * 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
US5858661A (en) * 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
WO2000047770A1 (en) * 1999-02-15 2000-08-17 Catalyst Biomedica Ltd. Susceptibility locus for osteoarthritis

Also Published As

Publication number Publication date
BR0305435A (en) 2005-01-11
EP1520044B1 (en) 2008-12-10
ES2319406T3 (en) 2009-05-07
JP2005532411A (en) 2005-10-27
WO2004007742A3 (en) 2004-06-17
JP2011093908A (en) 2011-05-12
EP1520044A2 (en) 2005-04-06
CA2491223A1 (en) 2004-01-22
JP2015038104A (en) 2015-02-26
WO2004007742A2 (en) 2004-01-22
ATE417128T1 (en) 2008-12-15
AU2003273428A8 (en) 2004-02-02
DE60325216D1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
AU3368497A (en) Human dnase i hyperactive variants
BR0013735A (en) Personal care and cosmetic composition
WO1996034953A3 (en) Cd16-ii variants
WO2001058918A3 (en) Oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments
EP1524961A4 (en) Cosmetic composition for care and/or treatment and/or makeup of the emulsion type structured with silicone polymers
EP1483366A4 (en) Antimicrobial composition
MXPA06000464A (en) Use of biotin or a biotin derivative for lightening skin and treating age spots.
WO1999033998A3 (en) Regulatory dna sequences of the human catalytic telomerase sub-unit gene, diagnostic and therapeutic use thereof
PT751778E (en) UTILIZATION OF WATER WITH REDUCED DETERIORATION FOR THE PRODUCTION OF HYGIENIC AND COSMETIC PREPARATIONS
IL122196A0 (en) Bicyclic-aromatic compounds
AU2108500A (en) Galenic formulation containing biotin
WO1999015643A3 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
BR0315437A (en) Hair treatment composition, uses and method of hair treatment
NZ329198A (en) Diaromatic propynyl or dienyl compounds
EP1582195A4 (en) Whitening agent, skin preparation for external use and cosmetic
WO2004033660A3 (en) Gene expression profiling from ffpe samples
AU2003273428A1 (en) Chromosome 6 and 9 genes involved in premature canities
AU2003220773A1 (en) Pharmaceuticals comprising shikonins as active constituent
WO2005073243A3 (en) Oligonucleotide and the use thereof for modulating an isoform c beta-1 protein-kinase in the form of a skin depigmentation agent
MX9805065A (en) Novel bi-aromatic dibenzofuran derivatives and their use in human and veterinary medicine and in cosmetics.
WO2004007764A3 (en) Chromosome 3, 5 and 11 genes involved in premature canities
PL2066409T3 (en) Use of quinoa extract as cosmetic and pharmaceutic slimming agent and/or as an agent preventing the formation of new fats in the human body
AU7402600A (en) New sequence variants of the human beta1-adrenoreceptor genes and use thereof
AU5052899A (en) Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase